Ascendis Pharma A/S (NASDAQ:ASND) vs. Avalo Therapeutics (NASDAQ:AVTX) Critical Review

Avalo Therapeutics (NASDAQ:AVTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.

Profitability

This table compares Avalo Therapeutics and Ascendis Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Earnings and Valuation

This table compares Avalo Therapeutics and Ascendis Pharma A/S”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60,000.00	10,958.40	-$78.26 million	($4.37)	-2.81
Ascendis Pharma A/S	$814.57 million	18.30	-$258.00 million	$12.89	18.53

Avalo Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

87.1% of Avalo Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Avalo Therapeutics and Ascendis Pharma A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1	0	12	0	2.85
Ascendis Pharma A/S	0	1	18	1	3.00

Avalo Therapeutics presently has a consensus price target of $45.10, indicating a potential upside of 267.86%. Ascendis Pharma A/S has a consensus price target of $309.26, indicating a potential upside of 29.45%. Given Avalo Therapeutics’ higher probable upside, equities research analysts clearly believe Avalo Therapeutics is more favorable than Ascendis Pharma A/S.

Volatility & Risk

Avalo Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Summary

Ascendis Pharma A/S beats Avalo Therapeutics on 9 of the 14 factors compared between the two stocks.

About Avalo Therapeutics

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.